Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Exclusion Criteria

• •Administration of an influenza vaccine within six months prior to study entry
• •Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.
• •Administration of a Tdap vaccine at any time prior to study entry.
• •Administration of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period.
• •History of diphtheria and/or tetanus and/or pertussis disease.
• •History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or influenza vaccine or any component of the study vaccines.